Key result
Natural phytochemicals markedly improve LVEF versus doxorubicin alone in preclinical models.
Its licence doesn't allow us to show a copy here.
Why the study?
Despite their historical use for cardiovascular disorders, the cardioprotective efficacy of natural phytochemicals from traditional medicinal plants against doxorubicin-induced cardiotoxicity remained unquantified.
Does natural phytochemical co-treatment improve cardiac function and reduce myocardial injury in rodent models of doxorubicin-induced cardiotoxicity?
Meta-Analysis (n=656)
Does natural phytochemical co-treatment improve cardiac function and reduce myocardial injury in rodent models of doxorubicin-induced cardiotoxicity?
Natural phytochemicals provide robust, multi-target cardioprotection against doxorubicin-induced cardiotoxicity in preclinical rodent models by modulating oxidative stress and mitochondrial dysfunction.
ETHNOPHARMACOLOGICAL RELEVANCE: Natural phytochemicals (NPs) derived from traditional medicinal plants, such as flavonoids from Glycyrrhiza uralensis, terpenoids from Salvia miltiorrhiza, and saponins from Panax ginseng, have been extensively used in ethnopharmacological practices across Asia for treating cardiovascular disorders. These include symptom complexes such as "xiongbi" (chest discomfort) and "xinji" (palpitations), which are analogous to modern doxorubicin-induced cardiotoxicity (DIC). Despite their historical use, the cardioprotective efficacy of these NPs against DIC and their alignment with traditional therapeutic principles remain unquantified. AIM OF THE STUDY: This study aims to provide quantitative evidence for the cardioprotective effects of NPs in preclinical DIC models, and to establish a mechanistic framework that bridges traditional uses with modern pharmacological understanding, thereby informing evidence-based integration of these ethnomedicinal agents into cardio-oncology practice. MATERIALS AND METHODS: A systematic review and meta-analysis was conducted following PRISMA guidelines, with protocol registered in PROSPERO (CRD420251050072). Four databases (PubMed, Web of Science, EMBASE, Cochrane Library) were searched for preclinical studies evaluating natural phytochemicals (NPs) in animal models of DIC. Effect sizes for cardiac function, myocardial injury, and oxidative stress were pooled using either fixed-effect or random-effects models based on heterogeneity (I RESULTS: A total of 33 preclinical studies comprising 656 rodents were included. NPs co-treatment significantly improved cardiac function (LVEF: SMD = 3.95, 95% CI [3.20, 4.70], P < 0.00001; LVFS: SMD = 3.73, 95% CI [2.95, 4.50], P < 0.00001) and reduced myocardial injury (CK-MB: SMD = -4.03, 95% CI [-4.88, -3.18], P < 0.00001; LDH: SMD = -3.39, 95% CI [-4.08, -2.71], P < 0.00001) compared to doxorubicin alone. This cardioprotection was accompanied by enhanced antioxidant defenses (SOD: SMD = 3.98, 95% CI [3.31, 4.66], P = 0.001; MDA: SMD = -3.78, 95% CI [-4.62, -2.95], P < 0.00001). Subgroup analyses revealed differential effects: flavonoids and phenolic acids primarily targeted redox imbalance and ferroptosis-related pathways; terpenoids and alkaloids were associated with preserved mitochondrial function; saponins and polyphenols showed antioxidant and anti-apoptotic effects. A limited number of studies further suggested that some NPs may exert preliminary cardio-oncological dual potential by conferring cardioprotection without compromising antitumor activity. CONCLUSION: This meta-analysis provides quantitative evidence that NPs confer robust, multi-target cardioprotection against DIC through coordinated modulation of oxidative stress, mitochondrial dysfunction, and regulated cell death. The mechanistic heterogeneity supports a stage-oriented and mechanism-informed classification strategy, offering a rational framework for integrating NPs into precision cardio-oncology.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2026) conducted a meta-analysis in Doxorubicin-induced cardiotoxicity (n=656). Natural phytochemicals (NPs) vs. Doxorubicin alone was evaluated on Cardiac function (LVEF) (SMD 3.95, 95% CI 3.20, 4.70, p=<0.00001). Natural phytochemicals significantly improved left ventricular ejection fraction compared to doxorubicin alone in preclinical models (SMD 3.95; 95% CI 3.20-4.70; P<0.00001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: